We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Expects More Litigation Over Generic Exclusivity
FDA Expects More Litigation Over Generic Exclusivity
October 26, 2010
A senior FDA attorney has admitted that Teva’s successful challenge of the agency’s policy for withdrawing a generic-drug maker’s exclusivity period caught the FDA off-guard and predicted the issue is almost certain to come up again.